Sanofi SA (SAN) Given Sell Rating at JPMorgan Chase & Co.
Sanofi SA (EPA:SAN)‘s stock had its “sell” rating reissued by equities research analysts at JPMorgan Chase & Co. in a research report issued on Tuesday.
Other equities research analysts have also issued reports about the company. Kepler Capital Markets set a €91.00 ($101.11) target price on Sanofi SA and gave the stock a “buy” rating in a report on Thursday, July 7th. Societe Generale set a €100.00 ($111.11) price target on Sanofi SA and gave the stock a “buy” rating in a report on Monday, August 1st. Berenberg Bank set a €93.00 ($103.33) price target on Sanofi SA and gave the stock a “buy” rating in a report on Thursday, September 8th. BNP Paribas set a €78.00 ($86.67) price target on Sanofi SA and gave the stock a “neutral” rating in a report on Wednesday, September 14th. Finally, Jefferies Group set a €76.00 ($84.44) price target on Sanofi SA and gave the stock a “neutral” rating in a report on Tuesday, September 13th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of €86.76 ($96.41).
Sanofi SA (EPA:SAN) opened at 69.50 on Tuesday. Sanofi SA has a one year low of €22.81 and a one year high of €69.50. The stock’s 50 day moving average is €26.01 and its 200 day moving average is €25.75. The firm has a market cap of €89.45 billion and a P/E ratio of 21.61.
Sanofi SA Company Profile
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.